Free Judgment - District Court of Delaware - Delaware

Case 1 :04-cv-00179-SLR Document 145 Filed 1 1/28/2007 Page 1 of 2
TN Tl-IE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
BAYER AG, BAYER HEALTHCARE AG, )
and BAYER PHARMACEUTICALS )
CORPORATION, )
Plaintiffs and )
Counterclaim Defendants, )
v. g Civil Action No. 04-179 (SLR)
DR. REDDY’S LABORATORIES, LTD. and )
DR. REDDY’S LABORATORIES, INC., )
Defendants )
and Counterclaimants. )
FINAL JUDGMENT ORDER
The Court, having conducted a trial in the above-referenced matter and having
issued its Opinion on October 25, 2007, hereby enters judgment in the above—referenced matter
as follows:
l. The moxifloxacin hydrochloride tablet product of Dr. Reddy’s
Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc.’s (collectively, "Reddy”) Abbreviated New
Drug Application ("ANDA") No. 76-938 iniiinges each of claims 1, 2, 8, and 9 of U.S. Patent
No. 4,990,517 ("the ’5 1 7 patent") and each of claims 1, 2, 3, and 4 of U.S. Patent 5,607,942
("the ’942 patent"). The bulk active pharmaceutical ingredient of Reddy’s DMP 16999 infringes
each of claims 1 and 2 of the *517 patent and each of claims 1, 2, 3 and 4 of the ’942 patent. The
use ofthe moxifloxacin hydrochloride tablet product of Reddy’s ANDA No. 76-938 when used
in accord with any Iabcl submitted now or in the future in Reddy’s ANDA 76-938 infringes each
ofclaims 1,2, 8, 9,and 11 of the ’517 patent and each of claims I, 2, 3, 4,5, and 7 ofthe ’942
patent ("the Asserted Claims").

Case 1:04-cv-00179-SLR Document 145 Filed 11/28/2007 Page 2 of 2
2.. The Asserted Claims ofthe ’5l 7 and ’942 patents are not invalid,.
3. The *517 patent and the ’942 patent are not unenforceable.
4. Pursuant to 35 U.S.C. § 27l(e)(4)(A), the effective date of any Food and
Drug Administration approval of Reddy’s ANDA No. 76-938 shall be no earlier than March 4,
2014.
5. Pursuant to 35 U.S.C. § 271(e)(4)(B), Reddy, their officers, agents,
attorneys and employees, and those acting in privity or concert with any of them, are hereby
enjoined from engaging in the commercial manufacture, use, offer for sale, or sale within the
United States, or importation into the United States, ofmoxitloxacin hydrochloride or any drug
product containing rnoxitloxacin hydrochloride or any other compound or drug product within
the scope of claims l or 2 ofthe ’942 patent prior to March 5, 2014, except as provided in 35
U.S,C. § 27l(e)(l).
6. Judgment is hereby entered in favor of Plaintiffs and against Defendants
on Plair1tiffs’ claims of infringement ofthe Asserted Claims.
7. Judgment is hereby entered in favor of Plaintiffs and against Defendants
on Defendants’ counterclaims that the Asserted Claims are invalid and that the ’51 7 and ’942
patents are unenforceable.
SO ORDERED tliissglhday of M“*-""h""/ , 2007
United States District Judge
2

Case 1:04-cv-00179-SLR

Document 145

Filed 11/28/2007

Page 1 of 2

Case 1:04-cv-00179-SLR

Document 145

Filed 11/28/2007

Page 2 of 2